SCHEMBL6154443

SCHEMBL6154443

O=COC(CCl)CNC(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TGM2 P21980 1/20 0.45
SYK P43405 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SLC1A3 P43003 1/20 0.43
SLC1A1 P43005 1/20 0.43
CTRB1 P17538 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
PLAU P00749 1/20 0.41
KEAP1 Q14145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154439 1.00 HTT (0.50) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6154638 0.82 ALDH1A1 (0.50) HTTLMNASMN1; SMN2SYKALDH1A1
SCHEMBL6153899 0.82 SLC6A2 (0.53) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6153940 0.82 ALDH1A1 (0.50) HTTLMNASMN1; SMN2SYKALDH1A1
SCHEMBL6153937 0.82 ALDH1A1 (0.50) HTTLMNASMN1; SMN2SYKALDH1A1
SCHEMBL6153903 0.82 SLC6A2 (0.53) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6153407 0.79 LMNA (0.55) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6153411 0.79 LMNA (0.55) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6153105 0.79 LMNA (0.55) HTTLMNASMN1; SMN2TGM2SYK
SCHEMBL6154371 0.78 HTT (0.49) HTTLMNASMN1; SMN2SYKL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215801-A1 Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates KANEKA CORPORATION (JP) 2005-09-29 US disclosed
EP-1553093-A1 PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES KANEKA CORPORATION (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215801-A1 Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates OXER1, RCC2, CBR3 HTT 3955/4885LMNA 3686/4885SMN1; SMN2 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.